Udo Holtick

Zamtocabtagene autoleucel in relapsed/refractory B-NHL: 5-year follow-up of a CD20/19 tandem CAR T-cell phase 1 trial

Hyatt Balke‐Want, Philipp Gödel, Christoph Schmid, Francis Ayuketang Ayuk et autres

ABSTRACT: Emerging long-term data indicate relapse rates of >50% after CD19-redirected chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). To reduce selective pressure on the CD19 antigen, we conducted a first-in-human phase 1 clinical trial …

de, us (code pays fourni par la source)

RWD183 Transplant Eligibility in DLBCL: A Real-World Analysis of German Hospital Billing Data

Ann-Cathrine Froitzheim, Tabea Poos, Melina Sophie Kurte, Udo Holtick et autres

de (code pays fourni par la source)

Enhancing the sequential flamsa-treosulfan conditioning regimen with venetoclax – first results from the multicenter flamsaclax Phase I/II trial

Felicitas Isabel Schulz, Udo Holtick, Mareike Verbeek, Edgar Jost et autres

Abstract Background: Sequential conditioning regimens are widely used to prepare patients with high-risk myeloid malignancies for allogeneic hematopoietic stem cell transplantation (alloHSCT). Venetoclax has been shown to act synergistically with hypomethylating agents (HMA) and conventional chemotherapy. Therefore, we initiated a Phase I/II …

de (code pays fourni par la source)

Hematopoietic Stem Cell Transplantation in an International Cohort of Colony Stimulating Factor‐1 Receptor ( CSF1R) ‐Related Disorder

Hemmo A. F. Yska, Marianne Golse, Shanice Beerepoot, Stefanie N. Hayer et autres

BACKGROUND: Colony stimulating factor-1 receptor (CSF1R)-related disorder (CSF1R-RD) is an autosomal dominant, rapidly progressive, demyelinating disease leading to death usually within a few years. Because of the central role of CSF1R in microglia functions, allogeneic hematopoietic stem cell transplantation (HSCT) has been …

fr, nl, de, br, es, ie, au (code pays fourni par la source)

Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma

Evgenii Shumilov, Julia Katharina Scholz, Maximilian Seib, Paolo Mazzeo et autres

ABSTRACT: Patients with large B-cell lymphoma (LBCL) who experience relapsed disease after CD19-directed chimeric antigen receptor (CAR) T-cell (CAR-T) therapy have a poor prognosis. Bispecific antibodies (BsAbs) induce complete remissions in ∼35% of these cases. Hypothesizing overlapping LBCL-intrinsic resistance mechanisms as well …

de, ch, at, sk, us (code pays fourni par la source)

Hematopoietic Stem Cell Transplantation in an International Cohort of Colony Stimulating Factor-1 Receptor (CSF1R)-Related Disorder

Hemmo A. F. Yska, Marianne Golse, Shanice Beerepoot, Stefanie Hayer et autres

Background: Colony stimulating factor-1 receptor (CSF1R)-related disorder (CSF1R-RD) is an autosomal dominant, rapidly progressive, demyelinating disease leading to death usually within a few years. Because of the central role of CSF1R in microglia functions, allogeneic hematopoietic stem cell transplantation (HSCT) has been …

Die Pathogeninaktivierung zur Gewährleistung einer qualitativ hochwertigen, sicheren und wirtschaftlichen Versorgung mit Thrombozytenkonzentraten in Deutschland

Matthäus Bauer, Andreas S. Buser, C. Dierks, Susan Halimeh et autres

Zusammenfassung Zielsetzung Die Pathogeninaktivierung (PI) ist ein weltweit anerkanntes Verfahren zur Verbesserung der Sicherheit von Thrombozytenkonzentraten und Plasma. Diese Arbeit untersucht die Notwendigkeit und potenziellen Vorteile der Implementierung der PI für Thrombozytenkonzentrate in Deutschland. Methodik Analysiert werden sowohl Daten zur aktuellen Blutversorgung …

de, ch, at (code pays fourni par la source)

Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma

Tim Richardson, Hishan Tharmaseelan, Lukas Peter Frenzel, Philipp Gödel et autres

Aggressive lymphomas are a heterogeneous group with a curative treatment approach. Advances in immunochemotherapy and salvage therapies, including CAR-T cells, have resulted in disease control or cure in up to two-thirds of patients. Allogeneic hematopoietic stem cell transplantation (aHSCT) remains a curative …

de (code pays fourni par la source)

Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults

Melanie Albrecht, Sebastian Theurich, Christof Scheid, Nicole Skoetz et autres

BACKGROUND: Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is an established treatment option for many malignant and non-malignant haematological disorders. Peripheral blood stem cells represent the main stem cell source in malignant diseases due to faster engraftment and practicability issues compared with bone …

de (code pays fourni par la source)

Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R/R LBCL

Giulia Magno, Kai Rejeski, Giulia Petra Rappa, Sophia Stock et autres

Management of relapsed/refractory Large B Cell Lymphoma (r/r LCBL) after CD19 Chimeric Antigen Receptor (CAR) T cells represents a major clinical challenge. Glofitamab and Epcoritamab, two CD3xCD20 bispecific T cell-recruiting antibodies, have recently been approved for third-line treatment. However, real-world experience with …

de, us, il, es (code pays fourni par la source)

Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma

Evgenii Shumilov, Rebecca Wurm‐Kuczera, Vladan Vučinić, Maximilian Seib et autres

Introduction Patients (pts) with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after CD19 chimeric antigen receptor (CAR)-T cell therapy are challenging to treat. CD20xCD3 T-cell-engaging bispecific antibodies (BsAbs) have emerged as a promising therapeutic option for these pts. In the pivotal …

de, ch, at (code pays fourni par la source)

Desiccation Stress Triggers and Exacerbates Experimental Ocular Graft-Versus-Host-Disease

Philipp Steven, Uta Gehlsen, Martina Maaß, Manolis Pasparakis et autres

Introduction: Ocular Graft-versus-Host Disease (oGVHD) is a rapidly progressing, sight-threatening condition of the eye following allogeneic hematopoetic stem cell transplantation (aSCT). Previously we reported in two retrospective studies, adverse environmental stress (AES) such as high air flow and low humidity during the …

de, us (code pays fourni par la source)